CA 15-3, CRP, and LDH correlates with prognostic parameters in canine mammary neoplasms

Abstract The identification of putative prognostic factors in canine mammary neoplasms (CMNs) has been focused on tissue-specific biomarkers, but the serum biomarkers, including cancer antigen 15-3 (CA 15-3), c-reactive protein (CRP), and lactate dehydrogenase (LDH) have been demonstrated to display clinical application in cases of CMNs. The aim of the study was to evaluate the levels of these serum biomarkers and their association with well-established prognostic factors in CMNs. Samples from 15 female canines with CMNs and 15 clinically healthy ones were collected. The results were evaluated using the Tukey’s, Pearson, or Spearman tests. The cut-off point, sensitivity, specificity, and area under curve (AUC) were evaluated using the receiver operating characteristic (ROC) curve analysis in a logistic regression model (P<0.05). The levels of CA 15-3, CRP and LDH were significantly higher in the serum of female dogs with CMNs compared to the healthy ones. Moreover, these factors were positively correlated with ulceration, tumor size, histopathological grade, metastatic lymph node, and clinical staging. Female dogs with CMNs were found to exhibit highest serum levels of CA 15-3, CRP, and LDH. Therefore, they can be applied to improve the efficacy of the diagnosis and prognostic evaluation in casas of CMNs.

[1]  Ê. Ferreira,et al.  Consensus Regarding the Diagnosis, Prognosis and Treatment of Canine and Feline Mammary Tumors - 2019 , 2020 .

[2]  J. Decock,et al.  Lactate Metabolism and Immune Modulation in Breast Cancer: A Focused Review on Triple Negative Breast Tumors , 2020, Frontiers in Oncology.

[3]  T. Shimura,et al.  Prognostic impact of interleukin-6 and C-reactive protein on patients with breast cancer. , 2019, Oncology letters.

[4]  N. Sood,et al.  Clinical Evaluation of Glycoproteins and Inflammatory Cytokines in the Serum of Dogs Affected with Canine Mammary Cancer , 2019, Proceedings of the National Academy of Sciences, India Section B: Biological Sciences.

[5]  S. Ryeom,et al.  Extracellular cyclic adenosine monophosphate‐dependent protein kinase A autoantibody and C‐reactive protein as serum biomarkers for diagnosis of cancer in dogs , 2018, Veterinary and comparative oncology.

[6]  G. Cassali,et al.  Mixed tumors of the canine mammary glands: Evaluation of prognostic factors, treatment, and overall survival , 2018, Veterinary and animal science.

[7]  F. C. Nunes,et al.  Epidemiological, clinical and pathological evaluation of overall survival in canines with mammary neoplasms , 2018, Arquivo Brasileiro de Medicina Veterinária e Zootecnia.

[8]  W. Łopuszyński,et al.  Changes in serum neopterin and C-reactive protein concentrations in female dogs with mammary gland tumours. , 2018, Polish journal of veterinary sciences.

[9]  M. Król,et al.  Current biomarkers of canine mammary tumors , 2018, Acta Veterinaria Scandinavica.

[10]  G. B. Roberto,et al.  Avaliação comparativa de dosagem do marcador tumoral CA 15-3 em cadelas hígidas ou com neoplasia mamária , 2018, Pesquisa Veterinária Brasileira.

[11]  Ahmed M. Kabel Tumor markers of breast cancer: New prospectives , 2017 .

[12]  Xing Li,et al.  High expressions of LDHA and AMPK as prognostic biomarkers for breast cancer. , 2016, Breast.

[13]  V. Heinemann,et al.  Tumor markers in the early detection of tumor recurrence in breast cancer patients: CA 125, CYFRA 21-1, HER2 shed antigen, LDH and CRP in combination with CEA and CA 15-3. , 2016, Clinica chimica acta; international journal of clinical chemistry.

[14]  G. Romieu,et al.  Serum HER2 extra-cellular domain, S100ß and CA 15-3 levels are independent prognostic factors in metastatic breast cancer patients , 2016, BMC Cancer.

[15]  Ê. Ferreira,et al.  HER-2, EGFR, Cox-2 and Ki67 expression in lymph node metastasis of canine mammary carcinomas: Association with clinical-pathological parameters and overall survival. , 2016, Research in veterinary science.

[16]  P. Pithua,et al.  Thymidine Kinase Type 1 and C‐Reactive Protein Concentrations in Dogs with Spontaneously Occurring Cancer , 2016, Journal of veterinary internal medicine.

[17]  Duane H. Hamilton,et al.  MUC1 upregulation promotes immune resistance in tumor cells undergoing brachyury-mediated epithelial-mesenchymal transition , 2016, Oncoimmunology.

[18]  Xian-fu Sun,et al.  Elevated Levels of Serum Tumor Markers CEA and CA15-3 Are Prognostic Parameters for Different Molecular Subtypes of Breast Cancer , 2015, PloS one.

[19]  Ê. Ferreira,et al.  Prognostic significance of tissue and serum HER2 and MUC1 in canine mammary cancer , 2015, Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc.

[20]  Z. Ševčíková,et al.  Determination of carcinoembryonic antigen and cancer antigen (CA 15-3) in bitches with tumours on mammary gland: preliminary report. , 2014, Veterinary and comparative oncology.

[21]  É. M. Rabelo,et al.  CA15.3, CEA and LDH in dogs with malignant mammary tumors. , 2012, Journal of veterinary internal medicine.

[22]  E. Manuali,et al.  CA 15–3 cell lines and tissue expression in canine mammary cancer and the correlation between serum levels and tumour histological grade , 2012, BMC Veterinary Research.

[23]  B. Nordestgaard,et al.  Elevated C-reactive protein in the diagnosis, prognosis, and cause of cancer , 2011, Critical reviews in clinical laboratory sciences.

[24]  J. Steiner,et al.  Biological variability of C-reactive protein and specific canine pancreatic lipase immunoreactivity in apparently healthy dogs. , 2011, Journal of veterinary internal medicine.

[25]  Q. Sun,et al.  Prognostic Role of C-Reactive Protein in Breast Cancer: A Systematic Review and Meta-Analysis , 2011, The International journal of biological markers.

[26]  E. Manuali,et al.  Cancer antigen 15/3: possible diagnostic use in veterinary clinical oncology. Preliminary study , 2010, Veterinary Research Communications.

[27]  F. Schmitt,et al.  The relationship between tumour size and expression of prognostic markers in benign and malignant canine mammary tumours. , 2009, Veterinary and comparative oncology.

[28]  L. Marconato,et al.  Serum lactate dehydrogenase activity in canine malignancies. , 2009, Veterinary and comparative oncology.

[29]  Y. Saco,et al.  Evaluation of serum haptoglobin and C-reactive protein in dogs with mammary tumors. , 2009, Veterinary clinical pathology.

[30]  A. Tvarijonaviciute,et al.  Serum Acute Phase Protein Concentrations in Female Dogs with Mammary Tumors , 2009, Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc.

[31]  A. Giatromanolaki,et al.  Serum and Tissue LDH Levels in Patients with Breast/Gynaecological Cancer and Benign Diseases , 2008, Gynecologic and Obstetric Investigation.

[32]  Michael A. Hollingsworth,et al.  Mucins in cancer: protection and control of the cell surface , 2004, Nature Reviews Cancer.

[33]  A. L. Jensen,et al.  Evaluation of a commercially available human C-reactive protein (CRP) turbidometric immunoassay for determination of canine serum CRP concentration. , 2003, Veterinary clinical pathology.

[34]  J. Lumsden Clinical Biochemistry of Domestic Animals. , 1998 .

[35]  Kimimasa Takahashi,et al.  Prognosis for canine malignant mammary tumors based on TNM and histologic classification. , 1996, The Journal of veterinary medical science.

[36]  I Iu IUDIN,et al.  [Tumors of the mammary gland]. , 1955, Meditsinskaia sestra.